Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05615623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05615623 · ClinicalTrials.gov record · last posted 2026-04-21

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorInSightec
Started2023-01-04
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 21, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2022-11-07; most recent amendment 2026-04-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-04-16
Status change Recruiting→Active, Not Recruitingv5
Trial Details
NCT Number NCT05615623
Lead Sponsor InSightec
Conditions Brain Tumor
Enrollment 10 participants
Start Date 2023-01-04
Primary Completion 2026-06 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-21